US Bancorp DE Sells 314 Shares of Inari Medical, Inc. (NASDAQ:NARI)

US Bancorp DE lessened its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 19.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,279 shares of the company’s stock after selling 314 shares during the quarter. US Bancorp DE’s holdings in Inari Medical were worth $53,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in NARI. Bessemer Group Inc. lifted its holdings in shares of Inari Medical by 16.4% during the first quarter. Bessemer Group Inc. now owns 2,439 shares of the company’s stock worth $117,000 after buying an additional 344 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Inari Medical by 7.7% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 4,852 shares of the company’s stock worth $234,000 after purchasing an additional 348 shares in the last quarter. Arizona State Retirement System increased its position in shares of Inari Medical by 2.5% during the second quarter. Arizona State Retirement System now owns 14,602 shares of the company’s stock valued at $703,000 after purchasing an additional 358 shares during the period. Covestor Ltd boosted its position in shares of Inari Medical by 30.2% during the 1st quarter. Covestor Ltd now owns 1,619 shares of the company’s stock valued at $78,000 after acquiring an additional 376 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Inari Medical by 83.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after buying an additional 435 shares in the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the sale, the chief executive officer now owns 445,310 shares of the company’s stock, valued at $22,265,500. The trade was a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director William Hoffman sold 40,000 shares of Inari Medical stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $50.05, for a total value of $2,002,000.00. Following the completion of the sale, the director now directly owns 561,233 shares in the company, valued at approximately $28,089,711.65. This represents a 6.65 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 126,000 shares of company stock worth $5,921,390. Corporate insiders own 10.60% of the company’s stock.

Inari Medical Stock Performance

Shares of NASDAQ:NARI opened at $50.56 on Monday. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $67.13. The company has a market capitalization of $2.96 billion, a PE ratio of -37.45 and a beta of 0.96. The company has a 50 day moving average price of $45.19 and a two-hundred day moving average price of $47.05.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. William Blair initiated coverage on Inari Medical in a research note on Thursday, July 25th. They issued an “outperform” rating on the stock. Stifel Nicolaus assumed coverage on shares of Inari Medical in a research note on Tuesday, September 17th. They issued a “hold” rating and a $50.00 target price for the company. Leerink Partners initiated coverage on shares of Inari Medical in a research note on Tuesday, September 3rd. They set a “market perform” rating and a $47.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Inari Medical in a research report on Tuesday, October 29th. Finally, Wells Fargo & Company reduced their price objective on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $58.89.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.